@article{oai:shiga-med.repo.nii.ac.jp:02000041,
 author = {辻, 俊一郎 and 土屋, 英明 and 岩谷, 千鶴 and 中村, 暁子 and 村上, 節 and TSUJI, Ichiro and MUKAI, Takeo and TSUCHIYA, Hideaki and IWATANI, Chizuru and NAKAMURA, Akiko and NAGAMURA-INOUE, Tokiko and MURAKAMI, Takashi},
 issue = {1},
 journal = {Reproductive medicine and biology},
 month = {Aug},
 note = {Purpose: 
This study aimed to explore whether umbilical cord-derived mesenchymal stem cells (UC-MSCs) could be used as a therapeutic resource for endometriosis. 
Methods: 
Of seven cynomolgus monkeys with endometriosis, five were administered UC-MSCs (intervention group) and two were administered saline (control group). First, intravenous US-MSC treatment was administered for three months. Second, weekly intravenous US-MSC administration combined with monthly intraperitoneal US-MSC administration was conducted for 3 months. Finally, weekly intraperitoneal US-MSC administration was conducted for 3 months. The dose of UC-MSCs was set to 2 × 106 cells/kg for all administration routes. Laparoscopic findings and serum cancer antigen 125 (CA125) levels were also evaluated. The Revised American Society for Reproductive Medicine classification was used for laparoscopic evaluation. 
Results: 
Laparoscopic findings showed exacerbation of endometriosis after intraperitoneal UC-MSC administration, although no changes were observed in the control group. Intravenous UC-MSC administration decreased the level of CA125 in all monkeys; however, the difference was not significant. Intraperitoneal UC-MSC administration significantly exacerbated endometriosis compared with intravenous administration (p = 0.02). 
Conclusions: 
This study revealed that intraperitoneal UC-MSC administration exacerbates endometriosis in a nonhuman primate model of the disease.},
 title = {Impact of administering umbilical cord-derived mesenchymal stem cells to cynomolgus monkeys with endometriosis},
 volume = {22},
 year = {2023},
 yomi = {ツジ, シュンイチロウ and ツチヤ, ヒデアキ and イワタニ, チヅル and ナカムラ, アキコ and ムラカミ, タカシ}
}